Related Experiment Videos
Use of new beta-lactam antibiotics in intraabdominal surgery
Abstract:
Infections after gastrointestinal surgery may involve both Gram-positive and Gram-negative aerobic and anaerobic microorganisms. Although the broadspectrum cephalosporins are active against most Gram-positive and Gram-negative bacteria, many of these agents are ineffective against Bacteroides fragilis, many clostridia and some strains of Escherichia coli, Pseudomonas aeruginosa and enterococci. These bacteria are frequently found in intraabdominal infections. A major reason for this inefficacy is susceptibility to beta-lactamases. The new beta-lactam antibiotics--cephamycins, third generation cephalosporins, carbapenems, acyl ureidopenicillins and monobactams--are all more or less beta-lactamase stable. The beta-lactamase inhibitors combined with a beta-lactam antibiotic give a broad antibacterial spectrum. Most of these compounds are non-toxic or relatively atoxic and, with the exception of the monobactams, they can be used as a monotherapy in many infections derived from the gastrointestinal tract. Antibiotic prophylaxis in colorectal surgery offers a clinical model for the study of the benefit and risks of new beta-lactam antibiotics. Most infections are derived from the gastrointestinal endogenous microflora. The study of the impact of different antibiotics on the colonic microflora indicates the risk of bacterial resistance, superinfection, antibiotic associated diarrhoea and pseudomembranous colitis. Data obtained from such studies with the new beta-lactam antibiotics are compared to the results from controlled clinical trials with these antibiotics in this review article.
Insights
New beta-lactam antibiotics and beta-lactamase inhibitors offer broader coverage for gastrointestinal surgery infections. They show promise in clinical trials, though risks like resistance and superinfection require careful monitoring.
Area of Science:
- Microbiology
- Pharmacology
- Surgical Infectious Diseases
Background:
- Gastrointestinal surgery infections involve diverse aerobic and anaerobic microorganisms.
- Broad-spectrum cephalosporins often fail against key pathogens like Bacteroides fragilis and Pseudomonas aeruginosa due to beta-lactamase activity.
- Intra-abdominal infections frequently harbor beta-lactamase-producing bacteria.
Purpose of the Study:
- To review the efficacy and safety of new beta-lactam antibiotics and beta-lactamase inhibitors for gastrointestinal surgery infections.
- To compare the performance of novel beta-lactam agents in clinical trials.
- To assess the impact of these antibiotics on colonic microflora and associated risks.
Main Methods:
- Review of existing literature on new beta-lactam antibiotics (cephamycins, carbapenems, etc.) and beta-lactamase inhibitors.
- Analysis of data from controlled clinical trials in colorectal surgery prophylaxis.
- Examination of studies on antibiotic impact on colonic microflora.
Main Results:
- New beta-lactam antibiotics and beta-lactamase inhibitors demonstrate enhanced stability against beta-lactamases, broadening antibacterial spectrum.
- These agents are generally non-toxic and suitable for monotherapy in many gastrointestinal infections.
- Antibiotic prophylaxis in colorectal surgery serves as a model for evaluating new beta-lactam benefits and risks.
Conclusions:
- New beta-lactam antibiotics and beta-lactamase inhibitors represent significant advancements in treating post-gastrointestinal surgery infections.
- Careful consideration of risks, including bacterial resistance, superinfection, and antibiotic-associated diarrhea, is crucial.
- Clinical trials provide valuable data for optimizing the use of these novel agents.